1.90
price up icon2.70%   0.05
pre-market  Pre-market:  1.96   0.06   +3.16%
loading
Vyne Therapeutics Inc stock is traded at $1.90, with a volume of 67,755. It is up +2.70% in the last 24 hours and down -23.54% over the past month. VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$1.85
Open:
$1.895
24h Volume:
67,755
Relative Volume:
0.67
Market Cap:
$28.90M
Revenue:
$486.00K
Net Income/Loss:
$-28.43M
P/E Ratio:
-0.674
EPS:
-2.8189
Net Cash Flow:
$-26.75M
1W Performance:
-18.45%
1M Performance:
-23.54%
6M Performance:
+3.26%
1Y Performance:
-7.77%
1-Day Range:
Value
$1.7701
$1.97
1-Week Range:
Value
$1.7701
$2.3491
52-Week Range:
Value
$1.57
$4.30

Vyne Therapeutics Inc Stock (VYNE) Company Profile

Name
Name
Vyne Therapeutics Inc
Name
Phone
800-775-7936
Name
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Name
Employee
13
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
VYNE's Discussions on Twitter

Compare VYNE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VYNE
Vyne Therapeutics Inc
1.90 28.90M 486.00K -28.43M -26.75M -2.8189
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-18-24 Initiated BTIG Research Buy
Dec-06-21 Resumed H.C. Wainwright Buy

Vyne Therapeutics Inc Stock (VYNE) Latest News

pulisher
Mar 08, 2025

VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

VYNE Therapeutics Reports Progress in Clinical Trials - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Est - GuruFocus.com

Mar 06, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Inc. (VYNE) reports earnings - Quartz

Mar 06, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga

Mar 06, 2025
pulisher
Mar 06, 2025

Vyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Can VYNE's $61.5M War Chest Drive Success in Vitiligo and Psoriasis Trials? - StockTitan

Mar 06, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics reports Q4 EPS (28c) vs (20c) last year - TipRanks

Mar 06, 2025
pulisher
Feb 27, 2025

VYNE Therapeutics (VYNE) Projected to Post Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 21, 2025

HC Wainwright Reiterates “Buy” Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

VYNE Therapeutics to Participate in March Investor Conferences - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

Can VYNE Therapeutics' March Investor Conferences Reveal New Strategic Directions? - StockTitan

Feb 20, 2025
pulisher
Feb 19, 2025

VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

VYNE Therapeutics Initiates Phase 1b Trial Of VYN202 For Plaque Psoriasis Treatment - Nasdaq

Feb 19, 2025
pulisher
Feb 19, 2025

Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - The Manila Times

Feb 19, 2025
pulisher
Feb 19, 2025

Can This New Psoriasis Drug Revolutionize Treatment? VYNE's Latest Clinical Trial Reveals Key Details - StockTitan

Feb 19, 2025
pulisher
Feb 17, 2025

Vyne therapeutics director Patrick Lepore buys $43,800 in stock - MSN

Feb 17, 2025
pulisher
Jan 20, 2025

VYNE Therapeutics Updates Corporate Presentation and Pipeline Progress - Defense World

Jan 20, 2025
pulisher
Jan 17, 2025

Vyne therapeutics director Patrick Lepore buys $43,800 in stock By Investing.com - Investing.com Australia

Jan 17, 2025
pulisher
Jan 17, 2025

Insider Buying: Patrick Lepore Acquires 15,000 Shares of VYNE Th - GuruFocus.com

Jan 17, 2025
pulisher
Jan 14, 2025

VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail

Jan 13, 2025
pulisher
Jan 10, 2025

Financial Analysis: Skye Bioscience (NASDAQ:SKYE) vs. VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Jan 10, 2025
pulisher
Jan 07, 2025

VYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligo - Yahoo Finance

Jan 07, 2025
pulisher
Jan 07, 2025

VYNE Therapeutics’ (VYNE) Buy Rating Reaffirmed at HC Wainwright - Defense World

Jan 07, 2025
pulisher
Jan 06, 2025

Forecasting The Future: 4 Analyst Projections For VYNE Therapeutics - Benzinga

Jan 06, 2025
pulisher
Jan 06, 2025

VYNE Therapeutics' (VYNE) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo - Marketscreener.com

Jan 06, 2025
pulisher
Jan 06, 2025

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluat - WICZ

Jan 06, 2025
pulisher
Jan 06, 2025

VYNE Therapeutics Completes Phase 2b Trial Enrollment for Novel Vitiligo Treatment VYN201 - StockTitan

Jan 06, 2025
pulisher
Jan 02, 2025

VYNE stock soars to 52-week high, touches $3.43 By Investing.com - Investing.com South Africa

Jan 02, 2025
pulisher
Jan 02, 2025

VYNE stock soars to 52-week high, touches $3.43 - Investing.com

Jan 02, 2025
pulisher
Dec 26, 2024

VYNE Therapeutics Reports Positive Phase 1a MAD Data for VYN202 - Defense World

Dec 26, 2024
pulisher
Dec 24, 2024

H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data - Yahoo Finance

Dec 24, 2024
pulisher
Dec 24, 2024

VYNE Therapeutics’ (VYNE) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Dec 24, 2024
pulisher
Dec 23, 2024

VYNE Therapeutics Reports Positive Phase 1a MAD Data for BD2-Selective BET Inhibitor VYN202 - Dermatology Times

Dec 23, 2024
pulisher
Dec 23, 2024

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor - The Manila Times

Dec 23, 2024
pulisher
Dec 15, 2024

Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Drops By 37.1% - Defense World

Dec 15, 2024
pulisher
Dec 12, 2024

VYNE Therapeutics Sees Strong Shareholder Support for Growth - TipRanks

Dec 12, 2024
pulisher
Nov 29, 2024

Prurigo Nodularis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therap - The Globe and Mail

Nov 29, 2024
pulisher
Nov 24, 2024

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 24, 2024
pulisher
Nov 19, 2024

VYNE Therapeutics initiated with a Buy at BTIG on I&I potential - Yahoo Finance

Nov 19, 2024
pulisher
Nov 18, 2024

BTIG Initiates Coverage of VYNE Therapeutics (VYNE) with Buy Recommendation - MSN

Nov 18, 2024
pulisher
Nov 11, 2024

VYNE Therapeutics’ (VYNE) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 11, 2024
pulisher
Nov 09, 2024

VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

VYNE Therapeutics Advances Clinical Pipeline in Q3 2024 - TipRanks

Nov 08, 2024

Vyne Therapeutics Inc Stock (VYNE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):